Literature DB >> 117703

Role of parenteral nutrition in patients with short bowel syndrome.

G F Sheldon.   

Abstract

More patients with extensive resection of the small bowel--secondary to regional enteritis, mesenteric infarction, cancer, etc.--are surviving perioperative treatment. To avoid nutrition-caused malabsorption and to maintain body composition, intravenous nutrition is initiated with a silastic atrial catheter in the immediate postoperative period. The patients are trained in "home hyperalimentation" procedures designed to allow normal nutrition to be maintained during the months required for bowel adaptation to occur. Because bowel adaptation to the absorption and transport of foodstuffs is in part dependent on the intraluminal presence of foodstuffs, elemental and regular diets are ingested during the period of intravenous support which may last for years. By using combined oral and intravenous nutrition, approximately 20 per cent of patients with short bowel syndrome eventually can take sufficient oral nutrients to sustain life.

Entities:  

Mesh:

Year:  1979        PMID: 117703     DOI: 10.1016/0002-9343(79)90644-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Total parenteral nutrition needs in different types of short bowel syndrome.

Authors:  M C Gouttebel; B Saint-Aubert; C Astre; H Joyeux
Journal:  Dig Dis Sci       Date:  1986-07       Impact factor: 3.199

Review 2.  Parenteral nutrition: current status and concepts.

Authors:  G D Phillips; C L Odgers
Journal:  Drugs       Date:  1982-04       Impact factor: 9.546

3.  Superior mesenteric vein thrombosis: a case report.

Authors:  W O Nedd; S M Siram; J A Bastien; L D Leffall
Journal:  J Natl Med Assoc       Date:  1985-09       Impact factor: 1.798

4.  100 patient-years of ambulatory home total parenteral nutrition.

Authors:  S J Dudrick; J J O'Donnell; D M Englert; R G Matheny; E R Blume; R E Nutt; M S Hickey; A O Barroso
Journal:  Ann Surg       Date:  1984-06       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.